category,datetime,headline,id,image,related,source,summary,url
company,1768529391,Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement,138147519,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,HSIC,Yahoo,"Henry Schein (HSIC) stock is in focus after the company secured exclusive U.S. distribution rights for CytoChipâ€™s FDA-cleared CitoCBC system, the first cartridge-based CBC device with a CLIA Waiver for point-of-care testing. See our latest analysis for Henry Schein. Investors have reacted positively to the CitoCBC agreement and recent M&A commentary, with the share price up 23.98% over the past 90 days and a 1-year total shareholder return of 8.82%. This suggests improving momentum after a...",https://finnhub.io/api/news?id=31392cf947faa25e0289add166cbf0b4990e66f4219b0ea9f6008696dac9a1e6
